EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment

Ofir Avitan iD, Tynisha Rafael, Manon Vreeburg iD, Laura Elst iD, Elise M Bekers, Maarten Albersen iD, Ekaterina S Jordanova, Oscar Brouwer iD

BJU International · 2024

DOI: 10.1111/bju.16473 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BJU International, 2024. Verfasst von Ofir Avitan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Imiquimod, Penile Neoplasms, Tumor Microenvironment, Carcinoma in Situ. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To provide an outline of the existing data on penile intraepithelial neoplasia (PeIN), as well as a narrative review on imiquimod (IQ; a toll‐like receptor 7 agonist) treatment and immune microenvironment markers that may predict response to treatment.

Methods

A narrative review of the literature from 2000 to the present was conducted on PubMed, and we describe the most relevant data and cross references.

Results

The incidence of PeIN is increasing. Local therapy with IQ may offer an easy applicable treatment with complete response rates of up to 63% but can be associated with considerable side‐effects. There is no conclusive data on the optimal treatment schedule for PeIN, but evaluation of treatment results for other human papillomavirus‐related pre‐malignancies suggest three times a week for a duration up to 16 weeks. There are no published studies concerning the PeIN immune microenvironment. However, findings from the few studies on penile cancer and pre‐cancerous vulvar and cervical lesions imply that specific immune cell subpopulations can serve as future predictors for successful immunomodulation treatments such as IQ.

Conclusions

Overall, limited data are available on IQ treatment for PeIN and no published data exists on the PeIN immune microenvironment. Further translational studies are warranted to gain more understanding on the pathophysiology of PeIN and potential predictors of progression and of response to topical treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImiquimodPenile NeoplasmsTumor MicroenvironmentCarcinoma in SituAntineoplastic AgentsHumansMaleIncidencePapillomavirus Infections

Stichwörter der Autor:innen

PeINhuman papillomavirusimiquimodimmune microenvironmentimmunotherapypenile cancer

Substanzen

ImiquimodAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Department of Urology, University Hospitals Leuven, Leuven, Belgium.
  • Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Ofir Avitan, Manon Vreeburg, Laura Elst, Maarten Albersen, Oscar Brouwer

Zitieren

APA

Avitan, O., Rafael, T., Vreeburg, M., Elst, L., Bekers, E. M., Albersen, M., Jordanova, E. S., & Brouwer, O. (2024). Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment. BJU International. https://doi.org/10.1111/bju.16473

Vancouver

Avitan O, Rafael T, Vreeburg M, Elst L, Bekers EM, Albersen M, et al. Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment. BJU International. 2024. doi:10.1111/bju.16473

BibTeX
@article{Avitan2024,
  author = {Avitan, Ofir and Rafael, Tynisha and Vreeburg, Manon and Elst, Laura and Bekers, Elise M and Albersen, Maarten and Jordanova, Ekaterina S and Brouwer, Oscar},
  title = {Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16473}
}
Kostenlos starten →